Abiomed Announces Q2 FY 2018 Revenue of $132.8 Million, Up 29% and Record U.S. Patient Utilization, Up 33%
October 26, 2017 07:00 ET
|
ABIOMED, Inc.
DANVERS, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2018 revenue of...
Abiomed's Impella® Technology that Enables Heart Recovery Showcased at TCT 2017 With More Than 30 Presentations
October 19, 2017 16:00 ET
|
ABIOMED, Inc.
DANVERS, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Abiomed Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announces that there are more than 30...
Abiomed Second Quarter Fiscal 2018 Earnings and Conference Call Notification
October 10, 2017 08:00 ET
|
Abiomed
DANVERS, Mass., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, October 26, 2017, the Company will release financial results for the second quarter of...
アビオメッド (Abiomed)、右心不全用インペラRP (Impella RP®) のFDA PMA承認を取得
September 22, 2017 17:28 ET
|
Abiomed
マサチューセッツ州ダンバース発, Sept. 23, 2017 (GLOBE NEWSWIRE) -- 画期的な心臓サポート･回復テクノロジーのリーダー的プロバイダー、アビオメッド (Abiomed, Inc.、NASDAQ:ABMD) は本日、インペラRP (Impella RP®) 心臓ポンプに対して米国食品医薬品局 (FDA) から市販前承認 (PMA)...
Abiomed recibe la Aprobación PMA de la FDA para Impella RP® y el tratamiento de la Insuficiencia Cardíaca Derecha
September 22, 2017 17:28 ET
|
Abiomed
DANVERS, Mass., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), un proveedor líder en asistencia cardíaca avanzada y en tecnología de rehabilitación, anunció hoy que ha recibido la...
Abiomed recebe aprovação PMA da FDA para a bomba cardíaca Impella RP® para insuficiência cardíaca direita
September 22, 2017 17:28 ET
|
Abiomed
DANVERS, Massachusetts, Sept. 22, 2017 (GLOBE NEWSWIRE) -- A Abiomed, Inc. (NASDAQ:ABMD), provedora líder de tecnologias revolucionárias de suporte e recuperação cardíacos, anunciou hoje que recebeu...
Abiomed ได้รับการรับรองผลิตภัณฑ์ก่อนออกสู่ตลาด (PMA) จาก FDA สำหรับ Impella RP® เพื่อใช้รักษาหัวใจห้องล่างขวาล้มเหลว
September 22, 2017 17:28 ET
|
Abiomed
แดนเวอร์ รัฐแมสซาชูเซตส์, Sept. 23, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD) ผู้นำเทคโนโลยีการช่วยเหลือหัวใจเลือดเล็ดลอดและการฟื้นสภาพหัวใจ...
Abiomed 的 Impella RP® 獲得美國食品藥物管理局 (FDA) 上市前核准 (PMA) 可用於治療右心衰竭
September 22, 2017 17:28 ET
|
Abiomed
馬薩諸塞州丹佛斯市, Sept. 23, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc.(NASDAQ:ABMD)，一間領先的突破性心臟支援及功能恢復技術供應商，今日發佈消息稱，公司的 Impella RP® 心臟泵獲得美國食品藥物管理局 (FDA) 上市前核准 (PMA)。歷經五年的研究工作告一段落，此項批准緊隨先前於 2015 年 1 月所獲得的 FDA...
아비오메드의 우심부전용 Impella RP®, FDA로부터 시판 전 허가(PMA) 획득
September 22, 2017 17:28 ET
|
Abiomed
미국 매사추세츠주 댄버스, Sept. 23, 2017 (GLOBE NEWSWIRE) -- 혁신적인 심장 보조장치 기술을 개발하는 선도기업 아비오메드(Abiomed, Inc.)(NASDAQ:ABMD)는 미국 식품의약국(FDA)으로부터 Impella RP® 인공심장 펌프에 대한 시판 전 허가(PMA)를 획득했다고 밝혔다. 지난 5년 동안 연구를 통해 개발한...
Abiomed获得FDA PMA批准其Impella RP®用于治疗右心衰竭
September 22, 2017 17:28 ET
|
Abiomed
马萨诸塞州丹弗斯, Sept. 23, 2017 (GLOBE NEWSWIRE) -- 突破性心脏支持和恢复技术的领先提供商Abiomed,Inc. (NASDAQ: ABMD) 今天宣布已收到美国食品和药物管理局（FDA）对于Impella...